- Home
- SWK vs MRNA Comparison
SWK vs MRNA Comparison
Compare SWK & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWK
- MRNA
- Stock Information
- Founded
- SWK 1843
- MRNA 2010
- Country
- SWK United States
- MRNA United States
- Employees
- SWK N/A
- MRNA N/A
- Industry
- SWK Industrial Machinery/Components
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SWK Consumer Discretionary
- MRNA Health Care
- Exchange
- SWK Nasdaq
- MRNA Nasdaq
- Market Cap
- SWK 13.8B
- MRNA 16.5B
- IPO Year
- SWK N/A
- MRNA 2018
- Fundamental
- Price
- SWK $80.90
- MRNA $40.43
- Analyst Decision
- SWK Hold
- MRNA Hold
- Analyst Count
- SWK 8
- MRNA 19
- Target Price
- SWK $100.00
- MRNA $79.50
- AVG Volume (30 Days)
- SWK 1.7M
- MRNA 7.7M
- Earning Date
- SWK 02-05-2025
- MRNA 02-20-2025
- Dividend Yield
- SWK 4.05%
- MRNA N/A
- EPS Growth
- SWK N/A
- MRNA N/A
- EPS
- SWK N/A
- MRNA N/A
- Revenue
- SWK $15,381,700,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- SWK N/A
- MRNA N/A
- Revenue Next Year
- SWK $1.92
- MRNA N/A
- P/E Ratio
- SWK N/A
- MRNA N/A
- Revenue Growth
- SWK N/A
- MRNA N/A
- 52 Week Low
- SWK $77.70
- MRNA $35.80
- 52 Week High
- SWK $110.88
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- SWK 34.77
- MRNA 42.87
- Support Level
- SWK $78.83
- MRNA $38.52
- Resistance Level
- SWK $82.70
- MRNA $40.83
- Average True Range (ATR)
- SWK 1.96
- MRNA 2.49
- MACD
- SWK 0.14
- MRNA 0.18
- Stochastic Oscillator
- SWK 27.90
- MRNA 29.98
About SWK Stanley Black & Decker Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates in two reportable segments namely Tools and Outdoor and Industrial. It generates maximum revenue from the Tools and Outdoor segment. The Tools and Outdoor segment is comprised of the Power Tools Group (PTG), Hand Tools, Accessories and Storage (HTAS), and Outdoor Power Equipment (Outdoor) businesses. Geographically, the company generates revenue from the United States, Canada, Other Americas, Europe, and Asia. It derives a majority of its revenue from the United States.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.